首页> 外文期刊>Alimentary pharmacology & therapeutics. >Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease.
【24h】

Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease.

机译:非酒精性脂肪肝患者内脏脂肪组织中miRNA的差异表达。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Progression of non-alcoholic fatty liver disease (NAFLD) can be facilitated by soluble molecules secreted by visceral adipose tissue (VAT). MicroRNAs (miRNAs) are likely to regulate some of these molecular pathways involved in pathogenesis of NAFLD. AIM: To profile miRNA expression in the visceral adipose tissue of patients with NAFLD. METHODS: Visceral adipose tissue samples were collected from NAFLD patients and frozen. Patients with biopsy-proven NAFLD were divided into non-alcoholic steatohepatitis (NASH) (n = 12) and non-NASH (n = 12) cohorts controlled for clinical and demographic characteristics. Extracted total RNA was profiled using TaqMan Human MicroRNA arrays. Univariate Mann-Whitney comparisons and multivariate regression analysis were performed to compare miRNA profiles. RESULTS: A total of 113 miRNA differentially expressed between NASH patients and non-NASH patients (P < 0.05). Of these, seven remained significant after multiple test correction (hsa-miR-132, hsa-miR-150, hsa-miR-433, hsa-miR-28-3p, hsa-miR-511, hsa-miR-517a, hsa-miR-671). Predicted target genes for these miRNAs include insulin receptor pathway components (IGF1, IGFR13), cytokines (CCL3, IL6), ghrelin/obestatin gene, and inflammation-related genes (NFKB1, RELB, FAS). In addition, two miRNA species, hsa-miR-197 and hsa-miR-99, were significantly associated with pericellular fibrosis in NASH patients (P < 0.05). Levels of IL-6 in the serum negatively correlated with the expression levels of all seven miRNAs capable of down regulating IL-6 encoding gene. CONCLUSIONS: miRNA expression from VAT may contribute to the pathogenesis of NAFLD - a finding which may distinguish relatively simple steatosis from NASH. This could help identify potential targets for pharmacological treatment regimens and candidate biomarkers for NASH.
机译:背景:内脏脂肪组织(VAT)分泌的可溶性分子可促进非酒精性脂肪肝疾病(NAFLD)的发展。微小RNA(miRNA)可能会调节NAFLD发病机理中的某些分子途径。目的:分析NAFLD患者内脏脂肪组织中miRNA的表达。方法:从NAFLD患者中收集内脏脂肪组织样品并冷冻。经活组织检查证实为NAFLD的患者分为非酒精性脂肪性肝炎(NASH)(n = 12)和非NASH(n = 12)受临床和人口统计学特征控制的队列。使用TaqMan Human MicroRNA阵列分析提取的总RNA。进行单变量Mann-Whitney比较和多元回归分析以比较miRNA谱。结果:NASH患者和非NASH患者之间共有113个miRNA差异表达(P <0.05)。其中,七项在多次测试校正后仍保持显着水平(hsa-miR-132,hsa-miR-150,hsa-miR-433,hsa-miR-28-3p,hsa-miR-511,hsa-miR-517a,hsa -miR-671)。这些miRNA的预测靶基因包括胰岛素受体途径成分(IGF1,IGFR13),细胞因子(CCL3,IL6),生长素释放肽/ obestatin基因和炎症相关基因(NFKB1,RELB,FAS)。此外,NASH患者的两种miRNA物种hsa-miR-197和hsa-miR-99与细胞周围纤维化显着相关(P <0.05)。血清中IL-6的水平与所有7种能够下调IL-6编码基因的miRNA的表达水平呈负相关。结论:增值税中的miRNA表达可能与NAFLD的发病有关-这一发现可能将相对简单的脂肪变性与NASH区别开来。这可以帮助确定药物治疗方案的潜在靶标和NASH的候选生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号